News
ATHXQ
0.0001
NaN%
--
Weekly Report: what happened at ATHXQ last week (0826-0830)?
Weekly Report · 6d ago
Weekly Report: what happened at ATHXQ last week (0819-0823)?
Weekly Report · 08/26 10:34
Healthcare bankruptcies slow after peaking in 2023: report
Seeking Alpha · 08/24 15:25
Weekly Report: what happened at ATHXQ last week (0812-0816)?
Weekly Report · 08/19 10:25
Weekly Report: what happened at ATHXQ last week (0805-0809)?
Weekly Report · 08/12 10:27
Weekly Report: what happened at ATHXQ last week (0729-0802)?
Weekly Report · 08/05 10:33
Weekly Report: what happened at ATHXQ last week (0722-0726)?
Weekly Report · 07/29 10:27
Weekly Report: what happened at ATHXQ last week (0715-0719)?
Weekly Report · 07/22 10:28
Weekly Report: what happened at ATHXQ last week (0708-0712)?
Weekly Report · 07/15 10:26
Weekly Report: what happened at ATHXQ last week (0701-0705)?
Weekly Report · 07/08 10:26
Weekly Report: what happened at ATHXQ last week (0624-0628)?
Weekly Report · 07/01 10:27
Weekly Report: what happened at ATHXQ last week (0617-0621)?
Weekly Report · 06/24 10:32
Weekly Report: what happened at ATHXQ last week (0610-0614)?
Weekly Report · 06/17 10:26
Weekly Report: what happened at ATHXQ last week (0603-0607)?
Weekly Report · 06/10 10:27
Weekly Report: what happened at ATHXQ last week (0527-0531)?
Weekly Report · 06/03 10:29
Weekly Report: what happened at ATHXQ last week (0520-0524)?
Weekly Report · 05/27 10:32
Weekly Report: what happened at ATHXQ last week (0513-0517)?
Weekly Report · 05/20 10:28
Weekly Report: what happened at ATHXQ last week (0506-0510)?
Weekly Report · 05/13 10:34
Weekly Report: what happened at ATHXQ last week (0429-0503)?
Weekly Report · 05/06 10:39
Weekly Report: what happened at ATHXQ last week (0422-0426)?
Weekly Report · 04/29 10:44
More
Webull provides a variety of real-time ATHXQ stock news. You can receive the latest news about Athersys Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATHXQ
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).